1. Heavy Menstrual Bleeding Max Brinsmead MB BS PhD Mayy 2015

2. This presentation will cover: Definitions & Diagnosis The evidence base for recommended management What tests are necessary & when Treatment –Medical & Surgical –Indications & Options –Risks & Side Effects

3. Resources: NICE Guidelines “Heavy menstrual bleeding” (January 2007) Cochrane database Pubmed Personal experience

4. A Few Definitions Menorrhagia –Excessive menstrual loss at regular intervals Metrorrhagia –Excessive menstrual loss without evidence of any cycling –Typical of anovulatory bleeding at the extremes of reproductive life Intermenstrual bleeding (IMB) –Episodes of bleeding between menstrual periods –Postcoital bleeding is a type of IMB The generic modern terms are Heavy Menstrual Bleeding (HMB) & Abnormal Uterine Bleeding (AUB)

5. Heavy menstrual bleeding is defined as: Excessive menstrual blood loss which interferes with a woman’s… –physical –emotional –social or –material quality of life This implies that the woman herself is the primary judge of severity And there can be substantial variation in tolerance to this dis - ease

6. While a pathological description is impractical: That is, the menstrual loss of an amount of blood loss that is likely to lead to health sequelae Because treatment options have risk & cost implications, a health provider is obliged to indicate to patients some criteria for diagnosis My criteria: –Sufficient to cause iron deficiency (exclude other causes) –Escapes from accepted menstrual protection –Requires changes > 4 hourly –Up at night more than once –Passage of large clots –Lasts for >7 days (full flow)

7. Menstrual Bleeding – What is Normal? One study of 179 normal women found that 97% menstruate for 3-8 days but the range is 1 – 19 days Most studies demonstrate an effect of age on the duration and amount of bleeding, as well as cycle length –For teenagers mean menstrual loss is 4.7 days, the mean cycle length is 30.8 days (10 th to 90 th centile range is 25 – 31days) –For ♀ >40 yrs mean menstrual loss is 4.1 days, the mean cycle length is 28.4 days (10 th to 90 th centile range is 25 – 32 days) –Mean measured loss is 34 ml at 15 yrs, peaks at 50 ml at 30 years then declines to 43 at 45 years Excessive blood loss is variously reported as >45, >80 or >120 ml based on when anaemia & iron deficiency begins But at least 30% of women who complain of HMB will have <80 ml blood loss

8. Incidence of Heavy Menstrual Bleeding The Impact on Women Cross sectional studies indicate that 5 – 50% of women will complain of “heavy periods” Quantified studies show that ≈ 10% of women will have menstrual losses that ≥ 80 ml Many studies indicate that the condition is associated with… –Reduced employment options –Work absences –Decreased earning capacity that for women are more important than such psychological effects as… –Depression and anxiety –Mood changes, irritability –As well as effects on social life, hobbies etc Can be summarised in “Quality of Life” measures

9. Fibroids Adenomyosis Endometriosis & Chronic PID Endometrial cancer Bleeding disorders – Idiopathic and acquired thrombocytopenia – Other known & undiagnosable disorders of coagulation Physiological – Includes dysfunctional uterine bleeding – All studies show >50% have no identified pathology Some Causes of Heavy Menstrual Bleeding

10. How many days does your period last for How many heavy days? What do you mean by heavy What do you use for menstrual protection How often do you change? Why do you change so often What do you use at night Do you change at night? How many nights Do you pass clots? How big are the clots? How often Any accidents (escape from menstrual protection) What do you mean by flooding Do you have to modify your life when you have your periods What do you do for contraception in your relationship Do you experience any other bleeding or bruising Are you taking iron tablets Some History-taking Tips

11. Consider the cultural context Explore parity, fertility requirements etc Consider occupation and activities The extent of examination and investigations will depend on –Age >45 –Intermenstrual bleeding –Any pelvic pain or pressure symptoms Details of any previous gynaecological interventions Other illnesses or conditions may influence treatment options Other symptoms may influence treatment choices –Infertility –Prolapse –Urinary incontinence Family History Other History-taking Essentials

12. A general examination of all patients –Height & weight –Signs of anaemia –Signs of endocrinopathy Thyroid Androgen excess Abdominal examination –For significant uterine enlargement Only rewarding in slim patients A palpable uterus is >12w size A vaginal examination is not required in primary care if there is no palpable uterus & a Pap smear is not required Unless a Mirena is planned But patients should not be sent for US without prior VE Examination

13. A Full Blood Count (FBC) for all patients –Look for iron-deficiency anaemia –Check the platelet count S Ferritin –Is the most sensitive indicator of Iron deficiency –But it is an acute phase reactant –Not required in primary care in the UK –Required in NZ for subsidised Mirena Thyroid function tests –Only when clinically indicated Female hormones –Have no role –Even when the diagnosis is dysfunctional uterine bleeding Laboratory Tests in Primary Care

14. Symptoms from menarche Positive Family History Other personal bleeding or bruising There is thrombocytopenia Tests to do: – Renal and Liver Function Tests – Bleeding time and Coagulation time – Seek specialist haematological advice The most commonly identified abnormality is von Willebrands Disease Indications for Tests of Coagulation Disorders

15. Ultrasound is the imaging of choice –But is not required unless the uterus is enlarged –Required for uncertainty after pelvic examination –Required after a failure of primary medical treatment Required information from this examination include: –Uterine size including length of the endometrial cavity –Myometrial abnormalities –Any adnexal pathology Considerable caution is required when... –Comments about endometrial thickness are reported as abnormal –Fibroids <4 cm in size are reported –Multiple fibroids are reported but there is no clinical evidence of an irregular uterus –Adnexal cysts <5 cm diameter are reported Imaging in Primary Care

16. What is the risk of significant pathology? This is mostly about the risk of endometrial cancer There are many studies… –Most do not distinguish between HMB and AUB The risk of endometrial Ca is age dependent –For women <30 yrs age the risk is 1:10,000 –For those >45 years the risk is 8:10,000 –And the risk of endometrial hyperplasia is ≈ 4X higher Who is at risk of Endometrial Cancer? –Those with intermenstrual bleeding –Those with irregular cycles – PCO disorder –Infertility –Obesity –Positive Family History

17. What is the chance of any pathology? There are many studies… –Most use ultrasound and hysteroscopy for Ix Overall about 30% have “significant fibroids” –But only ≈50% of patients with “significant fibroids” have HMB About 10% have endometrial polyps –But there is evidence that polyps cause HMB About 15% have endometriosis –But pain is more important for this disease Up to 50% of patients undergoing hysterectomy have Adenomyosis –But these are a selected group –And there is debate about what constitutes adenomyosis on histology Up to 20% patients with HMB have a coagulation disorder

18. Patient is >45 years of age There is irregular or intermenstrual bleeding The uterus is >10 weeks size There are symptoms or signs suggestive of such pelvic conditions as endometriosis, PID, adnexal pathology etc. Ultrasound suggests uterine fibroids >4 cm or distortion of the uterine cavity Failure of primary pharmaceutical treatment Patient request Indications for Referral

19. Information about the condition and options for treatment should be given prior to the specialist’s visit Written information to include... –expected outcome and its duration of effect –the type and frequency of risks, side effects and complications of all methods of treatment –any potential impact on fertility The patient should be involved in the treatment choice –But safety and cost effectiveness need to be borne in mind This may require time A second specialist opinion is sometimes required Patient Choice

20. How is pathology identified? There is no gold standard s hort of hysterectomy & histology The tools of investigation are best regarded as complementary and should be used selectively D&C is no longer regarded as an acceptable investigation Most studies have compared: – Transvaginal ultrasound (TVS) – Saline hysterography (SHG) – Hysteroscopy Which can be inpatient or outpatient Electrolyte, non-electrolyte distension medium or CO 2 Fixed or fibreoptic – With attention to the role of Endometrial Biopsy to exclude Ca

21. Which Test? What is the Evidence? Systematic Review of TVS (10 studies), Saline Hysterography (SHG, 11 studies) and Hysteroscopy (3 studies) for the identification of any pathology TVS –Sensitivity 48 – 100% –Specificity 12 – 100% SHG –Sensitivity 85 – 100% –Specificity 50– 100% Hysteroscopy –Sensitivity 90 – 97% –Specificity 62 – 93% Ultrasound better for the identification of fibroids HSG and Hysteroscopy better for the identification of polyps

22. Exclusion of Endometrial Cancer Hysteroscopy with biopsy will identify >99.5% of endometrial cancers Pipelle endometrial biopsy (an outpatient procedure) has an overall sensitivity of only 70% for endometrial pathology –Because it will often be negative with benign endometrial polyps But Pipelle has a 99% negative predictive value for endometrial cancer

23. Pipelle Endometrial Biopsy Is best done in association with ultrasound Indications: –Prior to therapy in patients at increased risk of endometrial cancer –Age >45 –Those with intermenstrual bleeding –Obese, Family history etc. Will be unsuccessful in up to 20% of patients No sample will be obtained in up to 50% –But that in itself may be diagnostic enough

24. Who Requires Hysteroscopy? High risk patient who has had a failed Pipelle Negative Pipelle but continuing symptoms Ultrasound findings inconclusive for submucous fibroid or endometrial pathology –A post menstrual study is required Failure of primary treatment Prior to endometrial ablation

25. Hormonal Levonorgestrel IUS (“Mirena”) Combined COC Cyclical oral Progestins Injected Progestin (“Depo Provra”) Danazol GnRH analogues Non Hormonal NSAIDs Tranexamic Acid (“Cyclokapron”) Medical Options for the Treatment of Heavy Menstrual Bleeding

26. Endometrial Ablation Hysteroscopic endometrial resection 2 nd generation techniques – Thermal balloon endometrial ablation (TBEA) – Microwave endometrial ablation (MEA) Myomectomy Uterine Artery Embolisation Hysterectomy Abdominal, vaginal or laparoscopic Subtotal or total With or without bilateral oophorectomy Surgical Treatment Options for Heavy Menstrual Bleeding

27. Potential unwanted outcomes Information for women about treatment for HMB

30. The Mirena IUS for HMB What is the Evidence? Systematic Review of 10 RCT’s that compare Mirena with other hormonal methods of treatment, endometrial ablation & hysterectomy Reduces mean menstrual loss by 71 – 96% Up to 50% of patients amenorrhoeic after 6m depending on age ≈ 85% patients are satisfied (and continuation rate) ≈ 1% rate of troublesome hormonal side effects When compared to endometrial ablation (EA) –Mean reduction in blood loss is greater with EA –But overall satisfaction equal –And Mirena better in the longer term (1 small study) When compared to hysterectomy –Overall satisfaction rates are equal –But Mirena is half the cost even when up to 40% of patients go on to hysterectomy

31. Oral Hormones for HMB What is the Evidence? Only one RCT of 45 patients for Combined oral contraceptive (COC) Mean blood loss (MBL) was reduced by 43% Better than Danazol and one NSAID but not another trialled Risks in older women and smokers plus side effects limit its use Progestin e.g. Norethisterone 5 mg TDS from Day 5 to 27 of a cycle is effective in reducing (MBL) –Luteal phase progestins are not effective Not as effective as NSAIDs and Tranexamic acid But MBL was reduced by 83% with long term use in 44 women CF Mirena (94%) and this difference is not significant Side effects are limiting – weight gain, headaches, acne, mood changes, mastalgia They are of most use in the short term treatment of DUB at the extremes of reproductive life

32. IM Depo Provera for HMB ≈10% of patients are amenorrhoic after 3m of 150 mg every 12w ≈50% amenorrhoic after 12m Continuation rates are low, however, presumably due to side effects And there is a small risk of bone mineral loss with long term use

33. GnRH analogues for HMB Most studies have been directed at the reduction of uterine size with these agents that induce a “reversible menopause” Reductions in uterine size up to 75% over 6m can occur And up to 90% of patients achieve amenorrhea This can be very useful prior to hysterectomy Oestrogen-deficiency symptoms i.e. hot flushes, vaginal atrophy and bone loss are limiting But these can be overcome with add-back therepy using small doses of oral oestrogen, COC, progestin or tibilone GnRH are currently very expensive drugs

34. Tranexamic Acid (Cyklokapron) for HMB Inhibits plasminogen activation but has no effect on blood clotting in healthy vessels Reduces fibrin breakdown in spiral arterioles Systematic reviews confirm that mean blood loss during menstruation is reduced by ≈ 50% 12% of women experience side effects Nausea, vomiting, dyspepsia Diarrhoea No apparent risk of thromboembolism Visual side effects are rare Dose 1G every 6 – 8 hours It is not contraceptive nor cycle regulating

35. NSAIDs for HMB Systematic reviews confirm that mean menstrual blood loss during menstruation is reduced by ≈ 30% Mefanamic acid e.g. Naprosyn better than Ibufren e.g. Indocid Side effects are well known but risk is reduced by intermittent use Dose 1 – 2 tablets 4 – 6 hourly Particularly useful when dysmenorrhoea is also a problem Not recommended if there is a known bleeding disorder loss

36. Summary of Non-Hormonal Drugs Rx Cyclokapron is more effective than NSAIDs But both can be used together And either can be continued long term if benefit is obtained But should be stopped if there is no response after 3 cycles Neither are contraceptive or cycle regulating NSAID is the drug of 1 st choice when there is concomitant dysmenorrhoea All of the trials excluded women with fibroids so their role in menorrhagia with fibroids is uncertain

37. Endometrial Ablation or Hysterectomy What is the Evidence? Systematic review 1999 of 5 RCTs with 706 patients Hysterectomy reduced MBL more (OR 0.12, CI 0.06 – 0.25) Greater patient satisfaction at 12m & 24m (OR 0.46, CI 0.24 – 0.88) Less pelvic pain on follow up (p<0.007) Better social functioning (p<0.007) Endometrial ablation had shorter hospital stay Fewer adverse outcomes More likely to require further surgery (OR 7.33, CI 4.18 – 12.86) (1:5 patients go on to hysterectomy) As a result hysterectomy is as cost effective as EA But is associated with ↑rate of long term urinary symptoms

38. Information for Patients that compares Endometrial Ablation & Hysterectomy

39. Endometrial Ablation Techniques All techniques are equivalent for outcomes but 2 nd generation techniques are: – Safer & Quicker – Easier to learn & perform Reduces MBL by 10 – 40 % Problems include: – Equipment failure – Continuing pelvic pain – Infection & Haematometra – Uterine perforation & fluid overload with hysteroscopic EA TBEA does not require prior endometrial thinning MEA best done in the 1 st half of the cycle

40. NICE Recommendations on Surgical Options Endometrial resection by a 2 nd generation technique be offered to all women with HMB provided that they have completed their family If the uterus is <10w in size and or fibroids < 3 cm diameter A hysteroscopic technique is used when there are submucous fibroids Practitioners and institutions be trained and competent for EA Hysterectomy, uterine artery embolisation or myomectomy be considered for fibroids >4 cm or uterus >10w size

41. Uterine Artery Embolisation (UAE) or Hysterectomy? 5 RCT’s 157+ patients showed that UAE better than hysterectomy in terms of: – Procedure time (Mean 16min less) – Less blood loss (minimal with UAE CF av. 400 ml for hysterectomy ) – Fewer lood transfusions – Shorter hospital stay (Mean 3.3 days less) – Quicker return to normal duties (Mean 27 days less) – Cheaper (UAE costs 65% those of hysterectomy) No difference between UAE and hysterectomy in terms of: – Patient satisfaction – Complication rates But UAE result in more readmissions (OR 6.00, CI 1.14 - 31.53) And 13 – 30% UAE patients require further surgery

42. Uterine Artery Embolisation (UAE) or Myomectomy? One RCT (n=?) and one cohort study (n=111) Myomectomy performed against UAE as for hysterectomy in terms of operating time, blood loss, hospitalisation and return to normal activities Equivalent results in terms of mean menstrual blood loss and complications But myomectomy better in terms of pelvic pain on follow up And fewer required re operation

43. NICE Recommendations for Uterine Fibroids For patients with heavy menstrual bleeding and fibroids >3 cm size (and especially those with pelvic pain or other symptoms) then… – Hysterectomy, Uterine artery embolisation (UAE) and myomectomy should all be offered – Myomectomy recommended if fertility is desired – Hysteroscopic resection of the entire fibroid with endometrial resection is appropriate if the fibroid (s) are submucous Pre treatment with GnRH analogue for 3 - 4m is worthwhile before hysterectomy and myomectomy – Reduces uterine size and makes surgery easier – Better HB pre op and less bleeding But GnRH analogues are contraindicated before UAE

44. Any Questions or Comments? Please leave a note on the Welcome Page to this website